secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2026-08-14T20:05:16+00:00
Accession:  0001193125-26-352186
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

NewAmsterdam Pharma appoints Robert Gunning as principal accounting officer
---------------------------------------------------------------------------

- Robert W. Gunning, 55, appointed principal accounting officer effective Aug 10, 2026, succeeding Louise Kooij (departs Aug 31, 2026).
- Gunning joined as VP Controller; base salary $375,000/year, target bonus 30% of base, prorated for first year.
- Equity grant: RSU covering 3,200 ordinary shares and option for 14,000 shares under 2024 Inducement Plan.
- Prior roles: Interim Controller at Altimmune (Apr-Jul 2026), VP Finance/Controller at Y-mAbs (2022-2026), VP Controller at Excision Biotherapeutics (2021-2022).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000119312526352186/0001193125-26-352186-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000119312526352186/nams-20260810.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-352186

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer